COMMUNIQUÉS West-GlobeNewswire

-
MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth
20/02/2024 - 15:00 -
PharmAla Data to be Published in ACS Chemical Neuroscience
20/02/2024 - 14:55 -
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
20/02/2024 - 14:38 -
Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call
20/02/2024 - 14:30 -
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
20/02/2024 - 14:30 -
Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® to Maine Dental Group, a Premier Group Practice with 21 Locations Across the Northeast
20/02/2024 - 14:30 -
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
20/02/2024 - 14:30 -
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
20/02/2024 - 14:30 -
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
20/02/2024 - 14:30 -
Lifeward to Report Fourth Quarter and Fiscal Year-End 2023 Financial Results on February 27, 2024
20/02/2024 - 14:30 -
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
20/02/2024 - 14:30 -
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
20/02/2024 - 14:05 -
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
20/02/2024 - 14:00 -
MIMEDX to Present at TD Cowen 44th Annual Health Care Conference
20/02/2024 - 14:00 -
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
20/02/2024 - 14:00 -
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
20/02/2024 - 14:00 -
Lisata Therapeutics to Present at BIO CEO & Investor Conference
20/02/2024 - 14:00 -
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
20/02/2024 - 14:00 -
Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference
20/02/2024 - 14:00
Pages